Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Abbott Laboratories (NYSE: ABT), an Illinois-incorporated healthcare company whose common shares are listed on the New York Stock Exchange. Through these filings, investors can review official disclosures on Abbott’s operations, governance, financial reporting practices and material corporate events.
Abbott’s SEC filings include periodic reports and current reports on Form 8-K. Recent 8-K filings describe matters such as the entry into an Agreement and Plan of Merger with Exact Sciences Corporation, under which a wholly owned Abbott subsidiary will merge with Exact Sciences, with Exact Sciences surviving as a direct, wholly owned subsidiary of Abbott subject to customary closing conditions. Another 8-K details a notice of a blackout period for certain employee benefit plans due to administrative changes, including recordkeeper, trustee and custodian transitions, and outlines related trading restrictions for directors and executive officers. Additional 8-K disclosures cover corporate governance updates, such as amendments to Abbott’s by-laws to change the size of the board of directors and the appointment of a new director, as well as announcements of quarterly financial results and the company’s use of non-GAAP financial measures.
On Stock Titan, each new Abbott filing from the SEC’s EDGAR system can be viewed alongside AI-powered summaries that explain key points in clear language. These summaries help readers quickly understand topics like merger terms, benefit plan blackout periods, board changes, or how management presents adjusted financial metrics, without having to parse every technical detail. Users can also review exhibits referenced in the filings, such as merger agreements, notices to directors and officers, and amended by-laws, to see the underlying legal documents.
For those tracking insider-related information, governance changes or major transactions, Abbott’s SEC filings offer an authoritative record of the company’s regulatory disclosures, while AI-generated insights on this page aim to make those documents more accessible and easier to interpret.
McDew Darren W reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Darren W. McDew received an equity award of 2,286 common shares-equivalent on a grant/award basis. The award is structured as a restricted stock unit grant under the Abbott Laboratories 2026 Incentive Stock Program and carries no cash purchase price.
The award will be settled in Abbott common shares on a one-to-one basis upon the earlier of his separation from service, death, or a change in control as defined in the program. After this grant, McDew directly holds 12,678 common shares, reflecting routine director compensation rather than an open-market share purchase.
Kumbier Michelle reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Michelle Kumbier received a grant of 2,286 restricted stock units. The award was made in the form of common shares without par value at no purchase price and is part of Abbott’s 2026 Incentive Stock Program.
The restricted stock units will be paid in Abbott common shares on a one-to-one basis upon the earlier of Kumbier’s separation from service, death, or a change in control as defined in the program. Following this grant, she directly holds 18,000 Abbott common shares.
Abbott Laboratories director Patricia Paola Gonzalez received an equity award tied to 2,286 common shares. The Form 4 shows an acquisition coded as a grant or award, with no cash price per share, reflecting stock-based compensation rather than an open-market purchase.
According to the footnote, this is a restricted stock unit award under the Abbott Laboratories 2026 Incentive Stock Program and will be paid in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. Following this award, Gonzalez directly holds 9,205 common shares.
Blount Sally E. reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Sally E. Blount received a grant of 2,286 restricted stock units under the Abbott Laboratories 2017 Incentive Stock Program. Each unit will be paid in one Abbott common share on the earlier of her separation from service, death, or a defined change in control. Following this award, she holds 36,344 common shares directly.
Babineaux-Fontenot Claire reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Claire Babineaux-Fontenot received a grant of 2,286 common shares on April 24, 2026, recorded at a price of $0.00 per share, as a stock-based award. Following this grant, she directly holds 7,603 Abbott common shares.
The award is structured as restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. According to the terms, the units will be settled on a one-for-one basis in Abbott common shares upon the earlier of her separation from service, death, or a change in control as defined in the program.
Ahuja Nita reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Nita Ahuja received an equity award of 2,286 common shares-equivalent as a restricted stock unit grant. The award was granted at a price of $0.00 per share under the Abbott Laboratories 2026 Incentive Stock Program.
The units will be settled in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. Following this grant, Ahuja’s reported direct holdings total 2,286 common shares.
ABT reported a Form 144 notice to sell restricted stock units tied to multiple grant dates. The filing lists planned dispositions by grant date ranging from 04/24/2009 to 04/25/2025, with per‑grant counts such as 2,465, 2,108, and others shown on the form.
The seller is recorded through UBS Financial Services, Inc. at the listed address and the filing date is 04/27/2026. The securities are Common stock registered on the NYSE.
Abbott Laboratories EVP and CFO Philip P. Boudreau reported multiple common share holdings and transactions dated April 23, 2026. A key event was an open-market purchase of 2,200 common shares at $91.50 per share, held indirectly through his spouse.
The filing also shows a discretionary transaction under Rule 16b-3(f) involving 8,909 common shares at $92.04 per share in a profit sharing trust, bringing that trust’s balance to 9,276 shares as of that date. Separately, Boudreau reports 71,172 common shares held directly after these transactions.
Abbott Laboratories reported that shareholders approved its new 2026 Incentive Stock Program, authorizing up to 140,000,000 common shares for equity-based awards. The plan lets the company grant stock options, restricted stock, restricted stock units, performance awards and other share-based incentives to employees and non-employee directors.
Kevin Conroy was named to Abbott’s Board of Directors, and the board size was increased from twelve to thirteen members effective April 24, 2026. Shareholders also elected the director slate and approved routine governance matters at the annual meeting.